Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
AstraZeneca
Dow
Johnson and Johnson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

OMNISCAN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Omniscan, and what generic alternatives are available?

Omniscan is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNISCAN is gadodiamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadodiamide profile page.

Drug patent expirations by year for OMNISCAN
Drug Prices for OMNISCAN

See drug prices for OMNISCAN

Recent Clinical Trials for OMNISCAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
i3 StatprobePhase 4
GE HealthcarePhase 4
BayerPhase 3

See all OMNISCAN clinical trials

Pharmacology for OMNISCAN

US Patents and Regulatory Information for OMNISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OMNISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007   Start Trial   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Johnson and Johnson
Mallinckrodt
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.